Laughing Gas, Serious Consequences: Recognizing Nitrous Oxide Toxicity in the Emergency Department

Background Nitrous oxide (N2O) is a colorless, sweet-smelling gas that acts primarily as a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, producing anxiolysis, anesthesia, and analgesia with acute use.1 In controlled settings (eg, dentistry, labor and delivery, and procedural sedation), it is valued for rapid onset, short duration, and predictable effects.1 Outside of health care, N2O is widely available in food and industrial products such as whipped cream chargers and large canisters, some of which are marketed for party or entertainment use.Figure 1: Recreationally used N2O products.Alongside increased availability, surveillance data demonstrate a marked rise in N2O-associated harm and emergency department (ED) presentations. National Poison Data System data from 2019 to 2024 show a greater than fourfold increase in reported N2O exposures, while other inhalant exposures have declined.2 Young adults aged 20 to 29 years demonstrate the highest prevalence of misuse, with rates higher among males than females.2 Most ED presentations reflect sequelae from chronic toxicity. Chronic, heavy N2O exposure inactivates vitamin B12 (cobalamin), causing functional deficiency and subsequent myeloneuropathy, hematologic cytopenias, and thromboembolic events.1,3 For emergency clinicians, N2O toxicity occupies an important intersection of substance use, neurology, and toxicology. Consider N2O misuse in patients (often younger adults) presenting with subacute paresthesias, ataxia, loss of proprioception, unexplained macrocytosis or cytopenias, or venous thromboembolism without clear provoking risk factors.1 Symptoms may follow weeks to months of use, but severe manifestations can also occur after short periods of high-volume exposure. Acute Toxicity Acute N2O intoxication typically presents with lightheadedness, euphoria, laughter, depersonalization, and altered perception, with symptoms occurring within minutes of use and rapidly resolving once exposure ceases.1 More severe presentations can include vomiting, aspiration, agitation or confusion, syncope, asphyxia, and hypoxia, particularly when N2O is inhaled in enclosed spaces or via balloons. Direct inhalation from pressurized canisters can cause frostbite of the lips and face, and gas expansion can result in barotrauma (eg, pneumomediastinum or pneumothorax). Trauma from high-risk behaviors while intoxicated is common, and polysubstance use can complicate the clinical picture. Management is supportive and focused on airway and oxygenation, trauma evaluation, and treatment of complications.1 Chronic Toxicity Chronic heavy N2O exposure inactivates cobalamin, causing functional deficiency and subsequent myeloneuropathy, hematologic cytopenias, and thromboembolic events.1,3 Clinically, patients often present with subacute gait disturbance and sensory change, unexplained macrocytic anemia or pancytopenia, or thromboembolism in a young, otherwise healthy patient. N2O oxidizes the cobalt atom in cobalamin, irreversibly impairing vitamin B12-dependent enzymes needed for myelin maintenance and DNA synthesis.4 A functional B12 deficiency can occur even when serum B12 concentrations are within the reference range. Methylmalonic acid (MMA) and homocysteine are often elevated.4 Demyelination can present over days to weeks with stocking-glove paresthesias, proprioceptive ataxia, fine motor deficits, and weakness.4 Hematologic consequences include macrocytosis and cytopenias, and elevated homocysteine contributes to a prothrombotic state with reported deep vein thrombosis, pulmonary embolism, and ischemic stroke.3,4 Emergency Department Evaluation A focused exposure history is essential (ie, duration, frequency, product type, and quantity), as patients may not recognize or disclose N2O as a drug. Ask using common terms such as whippets, balloons, Galaxy Gas, and nangs, and screen for concurrent substance use disorders. N2O does not appear on standard urine drug screens, and many patients do not volunteer it unless asked in plain language. A practical question is: “Have you used nitrous, whippets, whipped cream chargers, or large flavored canisters to get high?” A targeted neurologic exam should evaluate proprioception, sensory deficits, gait ataxia, weakness, and bowel or bladder dysfunction. Maintain a broad differential for subacute myelopathy and neuropathy, including spinal cord compression, transverse myelitis, multiple sclerosis, Guillain-Barré spectrum disorders, and other nutritional myeloneuropathies (eg, copper deficiency).1,4 Red flags that should lower the threshold for urgent imaging and admission include rapidly progressive weakness, frequent falls or inability to ambulate safely, bowel or bladder dysfunction, a sensory level, or significant objective motor deficits. MRI of the spine is reasonable when myeloneuropathy or sensory ataxia is suspected and may show dorsal column T2 hyperintensity, although early imaging can also be normal. Neurology consultation should occur early, and physical and/or occupational therapy and addiction services can support rehabilitation and cessation. Obtain a complete blood count with differential and serum vitamin B12 and consider MMA and homocysteine. Because N2O causes a functional cobalamin deficiency, serum B12 may be normal, so normal values should not be used to exclude N2O neurotoxicity when the clinical picture fits. When available, MMA and homocysteine can support the diagnosis and are often more informative than serum B12 alone. For thromboembolic events, follow standard diagnostic and therapeutic approaches, including systemic anticoagulation therapy when indicated. Consider N2O misuse and functional B12 deficiency as a contributing and potentially modifiable risk factor. Management The mainstay of treatment for suspected N2O neurotoxicity is immediate cessation of N2O use and intramuscular (IM) vitamin B12 supplementation.4 A recommended regimen is vitamin B12 1 mg IM daily for 1 to 2 weeks, followed by vitamin B12 1 mg IM weekly for 4 to 6 weeks, with longer-term dosing individualized in collaboration with neurology or hematology.4 It is reasonable for ED teams to administer the first dose when clinical suspicion is high, even before confirmatory testing results, because delays may worsen neurologic injury. Adjunctive folate and methionine are sometimes used, but evidence is limited. Folate should not be used as a substitute for B12 repletion. Disposition & Follow-up Patients with objective weakness, unsafe gait, frequent falls, bowel or bladder dysfunction, or concern for alternative emergent diagnoses generally warrant admission for expedited MRI, neurology evaluation, and rehabilitation planning. Patients with mild sensory symptoms and reliable follow-up may be discharged after the first vitamin B12 IM dose, strict cessation counseling, and arranged neurology follow-up, recognizing that neurologic recovery may be incomplete and can take weeks to months.1,4 When thromboembolism is present, treat per standard institutional pathways and protocols and consider N2O-associated functional vitamin B12 deficiency as a potentially modifiable contributor.